Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.

The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Latest Announcements


16/03/2017
Three Additional US Patents Granted
15/03/2017
ROTH Conference Presentation
15/03/2017
PTX presentation for 29th Annual ROTH Conference
08/03/2017
First Cohort Successfully Completed in Phase 1b/2 AML Trial
03/03/2017
PTX to present at 29th Annual Roth Conference
23/02/2017
Appendix 4D and Half Year Financial Report